facsimile
TRANSMITTAL

U.S. Nuclear Regulatory Commission

Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, Texas 76011
DIVISION OF NUCLEAR MATERIALS SAFETY

January 13, 2005

Name: Ron Frick, RSO

Organization: The Cancer Center of Hawaii, LLC
Fax: 808-373-7017
Phone: 808-373-7009

License No.: 53-27797-01
Docket No.: 030-36775
Control No.: 470300

Subject: New License Application dated December 8, 2004

Pages:

I have reviewed your application for a new license for The Cancer Center of Hawaii, LLC. The items on the following page are deficiencies which need to be addressed, prior to my completing the review of your application. Please respond to this fax within 15 days from the date of this fax. Our fax number is (817) 860-8263. If you have any questions regarding this fax, please call me at (817) 276-6552. When responding to this fax, please include the license, docket and control numbers located at the top of this page.

Please recognize that you may continue to do business under the St. Francis Medical Center license, because the respective authorizations still remain on that license. The St. Francis Medical Center license will be amended after The Cancer Center of Hawaii license is issued.

Thank you for your cooperation and assistance in expediting this matter.

/RA/

Rachel S. Browder, Health Physicist
DNMS/NMLB

1. Please provide the Total Activity that will be possessed at any one time for 35.400 material, which include the Paladium-103 and Iodine-125, used for manual brachytherapy.

2. Please provide the maximum amount of depleted uranium in kilograms for your license. NUREG-1556, Volume 9, section 8.5, provides an example of 999 kilograms of DU.

3. In reviewing the Emergency Procedures for HDR brachytherapy, please clarify the names of the individuals responsible fo implementing the corrective actions.

4. In reviewing the guidance document for GliaSite, it indicates that you would "provide instructions" to the staff involved with the treatment. Please clarify the training provided to the respective staff.

5. Please confirm that you will follow the manufacturer's procedures for administering the GliaSite or indicate your method of assuring that contrast medium will not inadvertently shield the dose.

6. How will you determine that the prescribed dose from the GliaSite was delivered? Will this be done by volumetric determination, radioactive content analysis, etc?

7. Please provide more detail on checking the patient for catheter leakage by taking radiation measurements for those patients who may be released under 35.75. What is the minimum time-frame for the post-injection survey, following the afterloading?